Immunogenicity analyses were also

performed on sub-populations of particular interest that were not specified in the protocol. These sub-populations included any subject who received OPV concomitantly (on the same day) with each of the 3 doses of PRV/placebo; subjects who did not receive OPV concomitantly with each of the 3 doses of PRV/placebo; subjects who received OPV concomitantly (on the same day) with Dose 1 of PRV/placebo; subjects who did not receive OPV concomitantly with Dose 1 of PRV/placebo, and subjects who were less than 6 weeks of age when they received Dose 1 of PRV/placebo. A total of 5468 (98.3%) subjects ON1910 out of 5560 subjects enrolled across the three sites were randomized into receiving either vaccine (n = 2733) or placebo (n = 2735). More than 95% of the subjects received all 3 doses of PRV (n = 2613) or placebo (n = 2612). The results of the efficacy analysis have been recently reported [15]. The immunogenicity cohort comprised 457

infants randomized to receive vaccine (n = 233, 51%) or placebo (n = 224, 49%) respectively; approximately 150 from each country. To evaluate the Rucaparib cell line immune responses to PRV in African subjects, several rotavirus-specific serological assays were utilized: (i) a serum anti-rotavirus IgA EIA, whose response is not type-specific, and (ii) SNA assays measuring the serotype-specific neutralizing antibody responses to each of the 5 human rotavirus serotypes contained in PRV (G1, G2, G3, G4, and P1A[8]). For the

independent pD1 and PD3 GMT analyses in the serum anti-rotavirus IgA EIA, 428 (220 PRV: 208 placebo) and 363 (192 PRV: 171 placebo) African infants were evaluable. For the pD1 determinations, there were 29 subjects with invalid data on laboratory determinations who were excluded from the immunogenicity analyses. For the PD3 determinations, there were 94 subjects with Resminostat either invalid data on laboratory determinations, or a positive rotavirus stool EIA result before 14 days PD3, or with samples taken outside the allowed time frame that were excluded from the final analyses. To measure the sero-response rate, a total of 358 (189 PRV: 169 placebo) subjects were evaluable. Overall, PRV was immunogenic with 148 infants who received the vaccine exhibiting a ≥3-fold rise in serum anti-rotavirus IgA in the total combined cohort (78.3%; 95%CI: 71.7, 84.0). The observed IgA response was similarly high in each of the African countries: Kenya (73.8%; 95%CI: 60.9, 84.2), Ghana (78.9%; 95%CI: 67.6, 87.7), and Mali (82.5%; 95%CI: 70.1, 91.3). However, 34 (20.1%) infants who received placebo across the three African countries showed an IgA response (95%CI: 14.4, 27.0), presumably to wild type infection. At the time of receipt of Dose 1 of PRV/placebo, there was no pre-existing anti-rotavirus antibodies detected in the serum samples as evidenced by the low GMT levels at pD1 (Table 1). At PD3, the overall GMT for anti-rotavirus IgA among PRV recipients was 28.